Technology | Nuclear Imaging | October 14, 2015

Gamma Medica Receives CE Mark for LumaGEM Molecular Breast Imaging System

Approval brings patients in Europe one step closer to improved screening for dense breast tissue

Gamma Medica, LumaGEM MBI system, molecular breast imagign, CE Mark approval

Image courtesy of Gamma Medica

October 14, 2015 — Gamma Medica Inc. announced the CE Mark approval allowing for the sale and distribution of the LumaGEM Molecular Breast Imaging (MBI) system within the European Economic Area (EEA). Gamma Medica is finalizing distribution partners in strategic markets across the EEA.

Breast cancer is the most common cancer affecting women in Europe, with nearly one in 10 women developing breast cancer before the age of 80. Dense breast tissue has been linked to an increased risk of breast cancer and a decrease in mammography sensitivity. These factors impact early detection efforts as both cancer and dense tissue appear white on the mammogram.

The LumaGEM MBI system addresses the critical shortcomings of mammography and other screening modalities in the early detection of breast cancer for the 50 percent of women with dense breast tissue. The system has been commercially available in the United States since obtaining approval by the U.S. Food and Drug Administration (FDA) in 2011.

A recent study conducted by Mayo Clinic, and published in two articles in the American Journal of Roentgenology (AJR) in 2015 determined that the addition of MBI, such as the LumaGEM MBI system, to an annual mammogram screening demonstrated a near 400 percent increase in invasive breast cancer detection rates. The combination also demonstrated a 50 percent reduction in biopsies and a subsequent 15 percent lower cost per cancer detected than screening with mammography alone.

The growing awareness of the limitations of mammography screening for women with dense breast tissue and the necessity for an effective adjunct screening technology led to the creation of LumaGEM MBI. Unlike mammography, tomosynthesis, ultrasound and magnetic resonance imaging (MRI) — all of which are anatomical imaging tests — MBI is a functional imaging modality that highlights metabolic activity in the breast and detects tumors not visible on a mammogram due to tissue density.

It is important for women to discuss with their doctors if MBI is an appropriate screening method for them. In addition to women with dense breast tissue or suspicious lesions, MBI may also be valuable for high-risk patients with a family history of breast cancer, patients who have tested positive for BRCA1 or BRCA2 genes, symptomatic patients, patients with cosmetic augmentation or patients who cannot receive an MRI.

For more information: www.gammamedica.com

Related Content

Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Ultrasound Imaging | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cardiac Imaging | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Siemens Healthineers Announces First Installation of Acuson Sequoia Ultrasound
News | Ultrasound Imaging | September 20, 2018
September 20, 2018 — Siemens Healthineers announced the first global installation of its newest...
LVivo EF Cardiac Tool Now Available for GE Vscan Extend Handheld Mobile Ultrasound
Technology | Cardiovascular Ultrasound | September 19, 2018
DiA Imaging Analysis Ltd. (DiA), a provider of artificial intelligence (AI)-powered ultrasound analysis tools,...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
Agfa Brings Intelligent Radiography to RSNA 2018
News | Digital Radiography (DR) | September 17, 2018
September 17, 2018 — At the 2018 Radiological Society of North America (RSNA) annual meeting, Nov.
Siemens Healthineers Announces First U.S. Install of Somatom go.Top CT
News | Computed Tomography (CT) | September 17, 2018
September 17, 2018 — The Ohio State University Wexner Medical Center in Columbus recently became the first healthcare
SmartCurve technology, a revolutionary breast imaging technology designed specifically for the curvature of the female breast to provide every woman with a more comfortable and accurate mammogram.
News | Mammography | September 14, 2018
Solis Mammography declared September Breast Wellness Month a
At RSNA 2018, radiology professionals will discover intelligent radiography powered by MUSICA, at Agfa's booth.

At RSNA 2018, radiology professionals will discover intelligent radiography powered by MUSICA, at Agfa's booth.

News | Digital Radiography (DR) | September 13, 2018
At RSNA 2018, radiology professionals will discover intelligent